Two snakebite antivenoms have potential to reduce Eswatini's dependency upon a single, increasingly unavailable product: results of preclinical efficacy testing
S. K. Menzies, T. Litschka-Koen, R. J. Edge, J. Alsolaiss, E. Crittenden, S. R. Hall, A. Westhorpe, B. Thomas, J. Murray, N. Shongwe, S. Padidar, D. G. Lalloo, N. R. Casewell, J. Pons, R. A. Harrison
This study evaluates two antivenoms as alternatives to SAIMR Polyvalent in Eswatini, finding they are equally or more effective against the most common snake venom but less effective against others.
bioRxiv · May 16, 2022Pharmacology & Toxicology